Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells

Am J Hematol. 2019 Sep;94(9):E245-E247. doi: 10.1002/ajh.25560. Epub 2019 Jun 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antigens, CD19 / therapeutic use*
  • Biological Products
  • Female
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, Follicular / blood*
  • Lymphoma, Follicular / therapy*
  • Male
  • Middle Aged
  • Neoplastic Cells, Circulating*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD19
  • Biological Products
  • obinutuzumab
  • axicabtagene ciloleucel